GlassScriptPhysician profile
Christopher Robert Roxbury
NPI 1497012694
$5,270.32
in general payments reported to CMS, 2019-2025
17 companies · $1,659 in 2025
The $1,659 reported for 2025 was more than what 87% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $174 · 2021: $284 · 2022: $884 · 2023: $1,329 · 2024: $512 · 2025: $1,659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,580 · Consulting Fee: $920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,579.51 |
| Consulting Fee | $920.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,423.85 | 2020-2025 | Core, Xpress Loprofile, Adherus Autospray Dural Sealant |
| Acclarent, INC | $1,272.80 | 2021-2023 | Trudi Nav Cable, Acclarent Aera, Acclarent Navwire |
| Medtronic, INC. | $709.77 | 2023-2025 | Propel |
| Integra Lifesciences Corporation | $328.72 | 2019-2025 | Acclarent Aera, Trudi Probe, Inspira Air |
| Neurent Medical Limited | $208.22 | 2024 | Neuromark Radiofrequency Console, Neuromark Device |
| Glaxosmithkline, LLC. | $194.73 | 2023-2025 | |
| Optinose US, INC. | $189.36 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $152.49 | 2023-2025 | Dupixent |
| Baxter Healthcare | $144.00 | 2019 | |
| Karl Storz Endoscopy-America | $142.43 | 2019 | |
| Depuy Synthes Sales INC. | $128.61 | 2025 | Matrixneuro |
| Aerin Medical INC. | $116.25 | 2025 | |
| Genzyme Corporation | $102.40 | 2025 | |
| Amgen INC. | $101.05 | 2025 | Tezspire |
| Regeneron Pharmaceuticals, INC. | $37.16 | 2024 | Dupixent |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $18.48 | 2025 | Immunocap |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Roxbury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.